Summit Therapeutics

Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Summit Therapeutics reports strong financials and strategic Akeso partnership

Summit Therapeutics showcased strong financials, promising clinical trial results, and a strategic partnership with Akeso for ivonescimab, positioning the company for growth.
While facing challenges around licensing agreements and international trial data acceptance, Summit's focus on oncology and global collaborations presents opportunities for future success.
With a solid financial foundation, innovative pipeline, and strategic vision, Summit is well-positioned to navigate challenges, capitalize on opportunities, and drive value for stakeholders.

Summit Therapeutics secures $5B deal for ivonescimab, shifts to oncology

Summit Therapeutics made a strategic move with a $5 billion transaction for ivonescimab, signaling a shift towards oncology-focused R&D.
While challenges exist in transitioning away from anti-infectives, Summit's strong financial position and Phase III progress offer promising opportunities.
The company's commitment to innovative therapies and strategic partnerships sets the stage for potential growth and market success.

Summit Therapeutics reports stable finances and progress in Phase III trials

Summit Therapeutics showcased resilience with a strong cash position despite reporting a net loss in Q2 2023.
The company's progress in Phase III trials and positive patient response data offer promise for future growth.
While facing challenges in trial execution and financial pressures, Summit has opportunities to advance its pipeline and attract investor support.

Summit Therapeutics advances ivonescimab in Q3 with strong financials

Summit Therapeutics is making significant strides in advancing ivonescimab for solid tumors, supported by strong financials and strategic partnerships. While facing challenges in differentiation and competitive landscape, the company is well-positioned to seize opportunities for growth and innovation. With a focus on operational excellence and clinical trial progress, Summit remains poised for future success.

Summit Therapeutics excels in Q4 with Ivonescimab progress and challenges

Summit Therapeutics showcased strong performance and financial stability, driven by advancements in Ivonescimab's trials and partnerships.
While facing challenges such as upcoming regulatory actions and timeline constraints, the company remains poised to leverage opportunities for market differentiation and growth.

Summit Therapeutics advances ivonescimab in oncology, eyes Phase III data

Summit Therapeutics made significant progress in Q1 2024, bolstered by strong financials and strategic collaborations. The company's focus on ivonescimab's potential in oncology, along with upcoming data releases, positions it for future success. Managing R&D expenses and leveraging key partnerships will be critical for sustained growth.

Summit Therapeutics advances ivonescimab with strong financial backing and collaborations

Summit Therapeutics made significant progress in clinical trials and regulatory milestones for ivonescimab, supported by strong financials and strategic collaborations.
While facing challenges in data disclosure and operational management, the company has opportunities to drive growth through further trial success and partnerships.
Overall, Summit Therapeutics is well-positioned to capitalize on its strengths and navigate challenges to unlock future opportunities in the competitive biopharmaceutical landscape.
Investors should monitor the company's continued progress in trials, partnerships, and financial management for insights into its long-term growth potential.

Summit Therapeutics advances ivonescimab with strong financial backing and global trials

Summit Therapeutics demonstrated strong performance in advancing ivonescimab, supported by robust financial management and operational efficiency.
While facing challenges in regulatory uncertainties and managing expenses, the company has opportunities to leverage positive trial outcomes and strategic expansions.
Overall, Summit Therapeutics' progress with ivonescimab presents a promising outlook for accelerated development and market growth in diverse tumor settings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Menlo Park, California, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Dr. Robert Booth, PhD, has been appointed to its Board of Directors, effective immediately.

Summit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of Directors

Geron

Party City Holdco

The Metals Co

Penny stocks for your September watch list. The post 4 Penny Stocks To Watch For September 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch For September 2022

The biotech's recent upward momentum is showing no signs of fading.

Why Summit Therapeutics Stock Popped Today

Applied DNA Sciences

TDH Hlds

Check these tips out for investing in penny stocks in September 2022 The post Investing in Penny Stocks in September? 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Investing in Penny Stocks in September? 3 Tips

Investors responded enthusiastically to key insider buying.

Why Summit Therapeutics Stock Is Soaring Today

OncoCyte

Marpai

The Dow Jones dropped by around 170 points on Wednesday following the release of Fed minutes. Investors, meanwhile, focused on some notable insider trades.

OncoCyte And 2 Other Stocks Under $1 Insiders Are Aggressively Buying

Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter ended June 30, 2022.

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022

Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the successful closing of its fully-subscribed $100 million rights offering.

Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering

Bob Duggan Remains Chairman of the Board of Directors and CEO Bob Duggan Remains Chairman of the Board of Directors and CEO

Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President

Menlo Park, CA, July 18, 2022 (GLOBE NEWSWIRE) --  Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to $100 million of the Company's common stock. The subscription rights will expire and have no value if they are not exercised prior to 5:00 pm Eastern Time on August 8, 2022, the expiration date (the “Expiration Date”).

Summit Therapeutics Announces Commencement of $100 Million Rights Offering

Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update with respect to the clinical development of ridinilazole, its lead Phase III product candidate for the treatment of patients with Clostridioides difficile infection (“C. diff. infection” or “CDI”).

Summit Therapeutics Provides Update on Ridinilazole

Menlo Park, CA, June 22, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company's Board of Directors has approved a rights offering available to all holders of record of the Company's common stock, par value $0.01 (the “Common Stock”) as of the close of the market on July 5, 2022 (the “Record Date”). The Company intends to distribute to all holders of Common Stock as of the Record Date non-transferable subscription rights to purchase shares of Common Stock at a price per share equal to the lesser of (i) $1.08 per share, the closing price of the Common Stock on June 22, 2022, or (ii) the volume weighted-average price of the Common Stock for the five consecutive trading days through and including the expiration date of the offering, currently contemplated to be August 5, 2022. Assuming that the rights offering is fully subscribed, the Company will receive gross proceeds of up to $100 million, less expenses related to the rights offering.

Summit Therapeutics Announces $100 Million Rights Offering

Rescheduled to June 16, 2022, at 1:00pm Eastern Time Rescheduled to June 16, 2022, at 1:00pm Eastern Time

Summit Therapeutics' Upcoming Annual Shareholders' Meeting

Cambridge, MA, June 01, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Ankur Dhingra has been appointed as Chief Financial Officer, effective immediately.

Summit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer

Cambridge, MA, May 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2022.

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022

Summit Therapeutics perceives multiple opportunities to expand across the microbiome therapeutics field Summit Therapeutics perceives multiple opportunities to expand across the microbiome therapeutics field

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021

Cambridge, Massachusetts, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company's Board of Directors has approved a rights offering available to all holders of record of the Company's common stock, par value $0.01 (the “Common Stock”) as of the close of the market on February 4, 2022 (the “Record Date”). The Company intends to distribute to all holders of Common Stock as of the Record Date non-transferable subscription rights to purchase shares of Common Stock at a price per share equal to the lesser of (i) $2.06 per share, the closing price of the Common Stock on January 21, 2022, or (ii) the volume weighted-average price of the Common Stock for the ten consecutive trading days through and including the expiration date of the offering, currently contemplated to be March 2, 2022. Assuming that the rights offering is fully subscribed, the Company will receive gross proceeds of up to $100 million, less expenses related to the rights offering.

Summit Therapeutics Announces Rights Offering

Cambridge, Massachusetts, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the Company's vision and its intended future development pathways at the 40th Annual J.P. Morgan Healthcare Conference at approximately 3:45 PM EST.  Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Operating Officer and a member of Summit's Board of Directors, will provide details regarding Summit's current plans with respect to its future research and clinical development goals.

Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Summit Therapeutics Inc. - SMMT

Cambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company's vision and its intended future development pathways at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at approximately 3:45 PM EST. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Operating Officer and a member of Summit's Board of Directors, will provide details regarding Summit's commitments towards its future research and clinical development goals, in addition to its current product pipeline.

Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference

LOS ANGELES, Dec. 31, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or "the Company") (NASDAQ: SMMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $SMMT #SMMT--INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the Firm

Summit Therapeutics Inc (NASDAQ: SMMT) shares are trading lower after disappointing results from the Phase 3 Ri-CoDIFy study of ridinilazole for C. difficile infection (CDI).

Summit Therapeutics' Infection Candidate Flunks In Head-To-Head Trial

The company just revealed disappointing phase 3 trial results for its only clinical-stage drug candidate.

Why Summit Therapeutics Stock Is Tumbling Today

Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline results for the Phase III Ri-CoDIFy study evaluating its investigational drug, ridinilazole, for the treatment of and Sustained Clinical Response (SCR) for patients suffering from C. difficile infection (C. diff. infection or CDI). The study showed that ridinilazole resulted in a higher observed SCR rate than vancomycin but did not meet the study's primary endpoint for superiority. SCR is defined as Clinical Response of the treated episode of CDI and no recurrence of the infection through 30 days after the end of treatment.

News for Summit Therapeutics Stock (SMMT)